Cell Cycle Inhibitors: CHK1/2 Inhibitors
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
5 Prior Therapies
Cell Cycle Inhibitors: CHK1/2 Inhibitors
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
---|---|---|---|---|
Drugs in Clinical Development | ||||
NCT02203513 | II | Prexasertib | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer | Promising activity in heavily pretreated BRCA WT patients, including those with CCNE1 alterations, but modest activity in BRCA MUT patients BRCA WT: BRCA MUT: pub 2018, abs May 2020 and poster |